Faruqi & Faruqi Investigates Possible Securities Claims Against Hims & Hers Health
Faruqi & Faruqi, LLP, a prominent national securities law firm, has announced an active investigation into potential legal claims regarding Hims & Hers Health, Inc. This probe focuses on the negative impacts that recent allegations have had on the company's stock performance and investor trust.
The investigation is particularly relevant for those who purchased Hims stocks between April 29, 2025, and June 22, 2025, as they might have the right to join a federal securities class action against the firm. A decision is needed by August 25, 2025, to assume the lead plaintiff role, a critical position in directing the class action's proceedings.
Hims & Hers, listed on the NYSE under the symbol HIMS, recently faced a turbulent time after Novo Nordisk announced it was terminating its partnership with the company. The decision by Novo Nordisk was predicated on allegations that Hims had participated in deceptive practices regarding the promotion and sale of compounded drugs that were falsely marketed. The group outlined that these drugs could potentially endanger patient safety due to inadequate regulatory compliance.
Following Novo Nordisk’s announcement, Hims' stock price fell significantly, dropping over 34% in a single day—a substantial blow for shareholders who had invested in the company based on its previously touted business prospects. The investigation aims to assess whether Hims and its executives misled investors with inaccurate or incomplete statements about the company's operations and strategic alliances.
It is essential for investors affected by this downturn to consider their legal options and seek guidance from attorneys such as those at Faruqi & Faruqi, who have successfully recovered significant funds for investors in the past. If you are interested in this class action or have pertinent information regarding Hims’ operations, contact Josh Wilson, a senior partner at Faruqi & Faruqi, at 877-247-4292 or 212-983-9330 (Ext. 1310) for further insights. This investigation underscores the importance of transparency and accountability for publicly traded companies and serves as a reminder for investors to maintain vigilance when reviewing their portfolios.
The investigation is particularly relevant for those who purchased Hims stocks between April 29, 2025, and June 22, 2025, as they might have the right to join a federal securities class action against the firm. A decision is needed by August 25, 2025, to assume the lead plaintiff role, a critical position in directing the class action's proceedings.
Hims & Hers, listed on the NYSE under the symbol HIMS, recently faced a turbulent time after Novo Nordisk announced it was terminating its partnership with the company. The decision by Novo Nordisk was predicated on allegations that Hims had participated in deceptive practices regarding the promotion and sale of compounded drugs that were falsely marketed. The group outlined that these drugs could potentially endanger patient safety due to inadequate regulatory compliance.
Following Novo Nordisk’s announcement, Hims' stock price fell significantly, dropping over 34% in a single day—a substantial blow for shareholders who had invested in the company based on its previously touted business prospects. The investigation aims to assess whether Hims and its executives misled investors with inaccurate or incomplete statements about the company's operations and strategic alliances.
It is essential for investors affected by this downturn to consider their legal options and seek guidance from attorneys such as those at Faruqi & Faruqi, who have successfully recovered significant funds for investors in the past. If you are interested in this class action or have pertinent information regarding Hims’ operations, contact Josh Wilson, a senior partner at Faruqi & Faruqi, at 877-247-4292 or 212-983-9330 (Ext. 1310) for further insights. This investigation underscores the importance of transparency and accountability for publicly traded companies and serves as a reminder for investors to maintain vigilance when reviewing their portfolios.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.